Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan? Do you suggest additional test sampling as time goes on? Would it provide us with any additional information?

Our Answer:

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens,  the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma.  However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.

Other Questions

Back to Help Center

Would we need to set up a Vet Portal for each doctor or just our hospital?

If you would like to set up accounts for the hospital, please send us a list of doctors' names and email addresses as well as any support staff who would need access to the Vet Portal. Each doctor can also register independently on the Vet Portal. Please note the report will be sent to the ordering veterinarian's email, not to all hospital accounts.

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.

I put the media tubes into the freezer. Can I still use the media tubes?

No, We will send you another batch of media tubes you could use. Please email us at support@imprimedicine.com or request fresh tubes online via our Vet Portal.

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.

How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.